Table 2.
Patient | Platelets at fostamatinib start (×109/L) | Platelet response (platelets ≥ 30 × 109/L) | Time to platelet response (days) | Peak platelet count (×109/L) | Most recent platelet count (×109/L) | Rescue therapy on fostamatinib | Adverse events | Remains on fostamatinib at most recent assessment | Died | Fostamatinib exposure (days) |
---|---|---|---|---|---|---|---|---|---|---|
1 | 20 | Yes | 181 | 140 | 74 | No | No | Yes | No | 252 |
2 | 19 | Yes | 0 | 102 | 75 | No | Transaminitis | Yes | No | 214 |
3 | 0 | No | 81 | 116 | 0 | Dex | Petechial rash, mild transaminitis | No | Yes | 175 |
4 | 193 | Yes | 0 | 193 | 126 | No | No | Yes | No | 152 |
5 | 27 | Yes | 5 | 94 | 18 | Dex and IVIG | Petechial rash | No | No | 216 |
6 | 25 | Yes | 19 | 162 | 162 | No | No | Yes | No | 188 |
7 | 31 | Yes | 46 | 141 | 37 | No | No | Yes | No | 93 |
Dex, dexamethasone; IVIG, intravenous immunoglobulin.